Clinical trial
Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis The Einstein-DVT Dose-finding Study. A Phase II Evaluation.
NCT00395772 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis The Einstein-DVT Dose-finding Study. A Phase II Evaluation.
- Lead sponsor
- Bayer
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2004
- Completion date
- December 31, 2005
- Enrollment
- 543 (actual)
- Sites
- 78
Conditions
As the registry lists them; a condition with its own page is linked.